- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02174510
A Pharmacokinetic Study of Lurasidone After Single Oral Administration in Healthy Subjects
To evaluate the pharmacokinetic (PK) characteristics of lurasidone after single oral administration of different doses in healthy Chinese subjects.
To evaluate the safety and tolerability of lurasidone after single oral administration of different doses in healthy Chinese subjects.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Single administration, double-blinded, placebo-controlled (3 subjects in each group will take placebo) and 3 dose groups (20 mg, 40 mg and 80 mg). There are three groups which are 20mg lurasidone or placebo, 40mg lurasidone or placebo and 80mg lurasidone or placebo.
This study comprises a screening period (between signing of the informed consent form and Day -2), baseline period (Day -1), treatment period (Days 1-3) and ending of study examination period (Days 8-11 after the last sample collection for PK evaluation).
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200031
- Xuhui Center Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- After detailed explanations of study objectives, methods and procedures, anticipated efficacy, pharmacologic actions, risks and other relevant contents, subjects are aware of all relevant information related to this study and have signed the written informed consent form voluntarily.
- Male subjects are 18≤ age <40 years of age when signing the informed consent.
- Subjects with body weight of 50.0≤ and ≤ 80.0 kg and BMI (body mass index) of 19.0≤ and <24.0 at screening examination.
- Subjects are able to comply with all requirements during this study period, receive various physical and laboratory examinations per study protocol, and report subjective symptoms.
Exclusion Criteria:
- Based on the examination results during screening period, various physical and laboratory examinations performed 1 day before medication (Day-1 ) and before administration of study drug on the medication day, there are certain medical concerns on subject's health status in principal investigator's or study supervising physician's opinions (certain treatment or medical observation are deemed necessary).
- Subjects with past diabetic history.
- Subjects has an HbA1c level of >6.2% at screening.
- Subjects with history of gastrointestinal operations.
- Because of subjects' past medical history of cardiovascular diseases, liver diseases, renal diseases, endocrine disorders, digestive diseases, hematologic diseases, respiratory diseases, mental illness, neurological disorders (especially epilepsy and other convulsive disorders) and other diseases, subjects are unsuitable to participate in this study in the principal investigator's or study supervising physician's opinions.
- Subjects with past history of allergy to drugs.
- Subjects have consumed grapefruit or food containing grapefruit ingredients between 7 days before medication (Day -7) and administration of study drug on the medication day (Day 1). Subjects have consumed food containing hypericum perforatum L. ingredients between 14 days before medication (Day-14) and administration of study drug on the medication day (Day 1).
- Subjects have taken any drugs (including over-the-counter drugs) between 7 days before medication (Day_-7) and administration of study drug on medication day.
- Regular drinker (criteria are mean daily consumption ≥2 bottles of 640 mL beers or Chinese liquor≥150 mL).
- Subjects are used to drink large amount (criteria are daily consumption>1.8 L) of caffeine-containing beverages (e.g. coffee, black tea, green tea, coca cola or nutritional oral solution, etc).
- Subjects have history of drug abuse or positive urine drug tests.
- Subjects with positive immunologic test results.
- Average amount of daily smoking>20 cigarettes.
- Subjects have taken other study drugs within 3 months (Day_-90~Day 1) before medication.
- Subjects received lurasidone orally before.
- Subjects have history of blood donations of 400 mL within 3 months (Day_-90~Day 1) before medication; 200 mL within 1 month (Day_-30~Day 1) before medication; or donation of blood components within 2 weeks (Day_-14~Day 1) before medication.
- Subjects have consumed alcohol-containing food between 3 days before medication 3 (Day_-3) and before administration of study drug on medication day.
- Subjects can not tolerate venipuncture or have poor peripheral venous access.
- Subjects are unwilling to abstain from vigorous exercise from Day_-1 until discharge.
- Other subjects who are unsuitable to participate in this study in principal investigator's or study supervising physician's opinions.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 20mg lurasidone
single oral lurasidone in 30 minutes after beginning of the over 350 kcal breakfast on day 1.The subjects will be follow up on day 8 to 11.
|
single oral lurasidone or placebo in 30 minutes after beginning of the over 350 kcal breakfast on day 1.
|
EXPERIMENTAL: 40mg lurasidone
single oral lurasidone in 30 minutes after beginning of the over 350 kcal breakfast on day 1.The subjects will be follow up on day 8 to 11.
|
single oral lurasidone or placebo in 30 minutes after beginning of the over 350 kcal breakfast on day 1.
|
EXPERIMENTAL: 80mg lurasidone
single oral lurasidone in 30 minutes after beginning of the over 350 kcal breakfast on day 1.The subjects will be follow up on day 8 to 11.
|
single oral lurasidone or placebo in 30 minutes after beginning of the over 350 kcal breakfast on day 1.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Lurasidone Cmax
Time Frame: pre-dose,0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose
|
Cmax:Maximum (peak) observed drug serum concentration.
|
pre-dose,0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose
|
Lurasidone AUC
Time Frame: pre-dose,0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose
|
AUC:Area under the serum concentration-time curve
|
pre-dose,0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose
|
Lurasidone Tmax
Time Frame: pre-dose,0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose
|
Tmax:Time to maximum (peak) drug serum concentration
|
pre-dose,0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose
|
Lurasidone λZ
Time Frame: pre-dose,0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose
|
λZ:Elimination rate constant
|
pre-dose,0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose
|
Lurasidone t1/2
Time Frame: pre-dose,0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose
|
t1/2 :Biological half life correlated with the elimination rate constant (kel) of semi-logarithmic concentration-time curve
|
pre-dose,0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose
|
Lurasidone MRT
Time Frame: pre-dose,0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose
|
MRT:Mean residence time.
|
pre-dose,0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose
|
Lurasidone CL/F
Time Frame: pre-dose,0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose
|
CL/F:Apparent total clearance.
|
pre-dose,0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose
|
Lurasidone VZ/F
Time Frame: pre-dose,0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose
|
VZ/F: Apparent volume of distribution at terminal phase (correlated with λz)
|
pre-dose,0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose
|
Collaborators and Investigators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Schizophrenia Spectrum and Other Psychotic Disorders
- Schizophrenia
- Physiological Effects of Drugs
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Agents
- Dopamine Agents
- Serotonin 5-HT2 Receptor Antagonists
- Serotonin Antagonists
- Dopamine D2 Receptor Antagonists
- Dopamine Antagonists
- Adrenergic alpha-Antagonists
- Adrenergic alpha-2 Receptor Antagonists
- Lurasidone Hydrochloride
Other Study ID Numbers
- D1070002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Rakitzi, StavroulaActive, not recruiting
-
Peking UniversityNot yet recruitingTreatment-resistant Schizophrenia
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
Clinical Trials on placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States